According to US-based ARS Pharmaceuticals, the company has raised $20 million in Series C financing for clinical development of its ARS-1 epinephrine nasal spray for the treatment of anaphylaxis. The financing round was led by Deerfield Management.
ARS said that it has submitted an IND for the intranasal epinephrine, which incorporates Aegis Therapeutics’ Intravail transmucosal absorption enhancement technology. The company said that pilot studies have demonstrated comparable PK for ARS-1 compared to intramuscular epinephrine.
ARS Pharmaceuticals President and CEO Richard Lowenthal commented, “Our focus is to get our novel intranasal epinephrine spray approved and into the hands of people to better protect themselves and their loved ones from risk of a severe allergic reaction that could lead to anaphylaxis. We feel fortunate to have Deerfield as an anchor investor and, together, we are working to realize our vision of potentially providing a reliable needle-free option that is easier to carry and use for the treatment of patients who experience severe allergic reactions.”
Read the ARS Pharmaceuticals press release.
